Insights · Sales & Teams

Cleared Device, No Sales? Check Your Launch Plan

A cleared device still needs a launch plan grounded in real use and buyer needs. Podcast guests describe the checks they make before wider sales.

MedTech · Stage 3: Discovery to Proposal · Sales & Growth

Short answer

How can a device team test launch readiness before its first sales?

Test launch readiness by checking user feedback, partner skills, cash needs, and the buying offer. Podcast guests describe seeking clinician input on production quality stock, choosing partners with launch experience, and funding the work of building sales. They also show why an offer must address the budget barrier buyers face.

Before the first sales, test the launch plan against real use, buyer needs, and cash. Guests on the Zero Friction Podcast describe work that still remains after a device gets cleared. Their examples point to user feedback, the right launch partners, and an offer buyers can fund.

What still needs testing with real users?

Gary Wakeford, Founder and CEO at Sonostik, describes a staged path to launch. At the time of the talk, he says the firm had clearance. Its next tasks were to raise cash and get production quality stock. That stock would then go to clinicians for real world feedback.

Wakeford wants that feedback before calling the product ready for market. He says small changes may still be needed at this stage. The aim is to get the product just as the users want it. In his plan, their feedback comes before a controlled release.

We feel the product is ready to go, but trying to be cautiously optimistic.

Gary Wakeford

His example makes the launch test quite specific. The team wants users to judge the stock it plans to sell. It is still seeking that judgment despite having clearance. The next step depends on what the clinicians say about the product.

For a launch team, that suggests a clear review task. Write down which user feedback the release plan still needs. Link that feedback to the product the team will ship. Note which changes remain open before the next release step. Those checks follow the sequence Wakeford describes. They keep the team's own belief in readiness open to user review.

Can the launch partner build demand from scratch?

Wakeford also describes talks with specialty distributor groups. He wants groups with experience in bringing a new product to market. He calls the work a missionary sale. In his account, it takes effort to get past the start. Recurring sales come after that work.

His partner search has a clear focus. He looks for both vascular access knowledge and a record of launch work. Those are the skills he wants for the first stage. He says market response and the rate of adoption will guide later choices.

That makes his plan more specific than a wish for broad reach. The question is what the partner knows how to do. Wakeford wants people who know the work of launching new technology. He does not describe expansion as a step already settled. More specialty distributors are a possible next step in his account.

A team can use that example to review its partner brief. Ask for a relevant launch story and the work it involved. Check how the group learned to build demand in that field. Keep the next expansion choice tied to market response. This applies Wakeford's stated criteria to the task of choosing a launch partner.

Will the cash last through the sales gap?

Tim Blair, Founder and CEO at iCHOR Vascular, describes a funding gap after clearance. In his account, a cleared device may still lack a buyer for the business. He says investors and strategic buyers want more proof of sales. Yet building those sales costs money.

Blair points to the cost of sales staff as part of that gap. He describes watching peer firms struggle with the commercial launch. Some had substantial funds, in his telling. He says the return on the sales effort can take a long time.

These are Blair's observations, rather than a forecast for every device firm. His warning concerns the work between a cleared product and proven sales. A plan still needs to fund that work. Clearance does not settle the sales costs he describes.

For a launch review, put those costs beside the proof still sought. Which sales tasks does the team need to fund? What proof does it expect those tasks to produce? What happens if that proof takes longer to build? Blair's example gives the team a reason to ask those questions. It does not supply a fixed budget or a promised sales date.

Does the offer fit the buyer's budget?

Tad Hartlaub, Managing Director and Co-Founder at MedVance Marketing, starts with market fit. He wants teams to learn how a device meets a market need. He also asks how it fits the work clinicians do. He says this work should start early.

Hartlaub then gives a case from his corporate career. An operating room lighting system had support from surgeons and room managers. In his account, the cost still faced pushback from senior leaders. It competed with other large purchases, such as imaging equipment.

The response was to change the offer. Hartlaub describes a lease that could fit the room's operating budget. He says that route helped the facility bring in the system faster. The example concerns the buying plan as well as the product's appeal.

Hartlaub also stresses the needs of the other people in the decision. He names finance leaders as part of that group. His point is that clinical interest leaves other concerns to address. His lighting example shows how his team responded to one of them.

A launch team can check its offer in the same spirit. Write down the budget barrier buyers describe. Ask how the proposed purchase fits their spending process. Review that barrier with the people who face it. Hartlaub's lease is an example of a response to a specific barrier. It is not a reason to assume every device needs that model.

What to do next before a wider launch?

Use these guest examples to check what the next launch step depends on. Wakeford waits for user feedback before a controlled release. Blair calls attention to the cash needed to build sales proof. Hartlaub shows an offer changed to meet a budget concern.

  • Check use. List the user feedback still needed before release. Use Wakeford's sequence to link that review to production quality stock.
  • Check the launch effort. Review partner launch experience and the cost of building sales. Use Wakeford's partner criteria and Blair's funding warning to frame that review.
  • Check the offer. Name the buyer's budget barrier and test the proposed buying route. Use Hartlaub's lighting case to make that discussion concrete.

The pattern across these episodes is a launch built around unresolved tasks. Each guest names work beyond having a product ready to show. Put that work into the next review before choosing a wider release.

Where this fits: stage 3 of the revenue funnel, Discovery to Proposal. Read what revenue friction is and how it is measured. See how RevRx AI works with MedTech teams.

This article shares general views on commercial strategy. It is not medical, legal, financial or regulatory advice.

Next step

Is this friction slowing your revenue?

Take the MedTech Revenue Scorecard or book a free Discovery Call.

Free 30-minute call: a commercial snapshot of your business (one strength, weakness, opportunity and threat, prepped before we talk) and your top priority fixes.